Regencell Bioscience Holdings has seen a very large share price gain over the past three years, yet recent weakness now has investors asking whether the current US$5.63 level still lines up with the business on a simple book value basis. With such a sharp swing in the recent share price record, the central issue is how much of the move book equity can reasonably support. Over the last three years the stock has delivered a return of more than 10x. This puts a lot of weight on the question of...
Regencell Bioscience Holdings has seen its share price swing sharply in recent years, which puts fresh focus on whether the current US$7.67 level lines up with what its balance sheet and book value can support. With the spotlight back on the stock after a series of setbacks and scrutiny, the key issue for you is how that market price stacks up against what the business has actually built up in net assets. Over the past 5 years the stock has delivered a very large gain of about 20 times,...
This is the newest page. Registered accounts read further back.